Data Request Form

Publications

296 publications

Publications in 2025

  1. Feng Y, Cao SQ, Shi Y, Sun A, Flanagan ME, Leverenz JB, Pieper AA, Jung JU, Cummings J, Fang EF, Zhang P, Cheng F — Human herpesvirus-associated transposable element activation in human aging brains with Alzheimer's disease Alzheimer's & dementia : the journal of the Alzheimer's Association. View source
  2. Dou L, Xu Z, Xu J, Zang C, Su C, Pieper AA, Leverenz JB, Wang F, Zhu X, Cummings J, Cheng F — A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson's disease NPJ Parkinson's disease. View source
  3. Cieri F, Di Francesco G, Cross CL, Bender A, Caldwell JZK — Dynamic neurocognitive adaptation in aging: Development and validation of a new scale Alzheimers Dement (N Y). View source
  4. Rhoads T, Wong CG, Cobos K, O'Bryant SE, Kind AJH, Miller JB; Health and Aging Brain Study (HABS‐HD) Team — Differential associations of neighborhood disadvantage, race/ethnicity, and cognitive status with experiences of psychosocial distress in the HABS-HD cohort Alzheimers Dement. View source
  5. Elhage A, Cohen S, Cummings J, van der Flier WM, Aisen P, Cho M, Bell J, Hampel H — Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway Alzheimers Dement. View source
  6. Pulukuri SV, Fagle TR, Trujillo-Rodriguez D, van Amerongen S, Bernick C, Geda YE, Wethe JV, Peskind ER, Katz DI, Alosco ML, Palmisano JN, Tripodis Y, Adler CH, Balcer LJ, Reiman EM, Shenton ME, Cummings JL, Stern RA; DIAGNOSE CTE Research Project — Characterizing Neurobehavioral Dysregulation Among Former American Football Players: Findings From the DIAGNOSE CTE Research Project J Neuropsychiatry Clin Neurosci. View source
  7. Cummings JL, Zhou Y, Van Stone A, Cammann D, Tonegawa-Kuji R, Fonseca J, Cheng F — Drug repurposing for Alzheimer's disease and other neurodegenerative disorders Nat Commun. View source
  8. Calvin-Dunn KN, Mcneela A, Leisgang Osse A, Bhasin G, Ridenour M, Kinney JW, Hyman JM — Electrophysiological insights into Alzheimer's disease: A review of human and animal studies Neurosci Biobehav Rev. View source
  9. Zhan H, Cammann D, Cummings JL, Dong X, Chen J — Biomarker identification for Alzheimer's disease through integration of comprehensive Mendelian randomization and proteomics data J Transl Med. View source
  10. Zhong K, Cummings J — A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease Expert Rev Neurother. View source
  11. Xu J, Song W, Xu Z, Danziger MM, Karavani E, Zang C, Chen X, Li Y, Paz IMR, Gohel D, Su C, Zhou Y, Hou Y, Shimoni Y, Pieper AA, Hu J, Wang F, Rosen-Zvi M, Leverenz JB, Cummings J, Cheng F — Single-microglia transcriptomic transition network-based prediction and real-world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease Alzheimer's & dementia : the journal of the Alzheimer's Association. View source

Publications in 2024

  1. Feng Y, Yang X, Hou Y, Zhou Y, Leverenz JB, Eng C, Pieper AA, Goate A, Shen Y, Cheng F — Widespread transposable element dysregulation in human aging brains with Alzheimer's disease Alzheimer's & dementia : the journal of the Alzheimer's Association. View source
  2. Carlson SJ, Chiu YF, Landers MR, Fritz NE, Mishra VR, Longhurst JK — Dual-Task Performance and Brain Morphologic Characteristics in Parkinson's Disease Neurodegener Dis. View source
  3. Klil-Drori S, Bodenstein KC, Sun S, Kojok L, Gruber J, Ghantous Y, Cummings J, Nasreddine Z — Montreal Cognitive Assessment (MoCA) XpressO: Validation of a digital self-administered cognitive prescreening tool J Am Geriatr Soc. View source
  4. Feldman HH, Cummings JL, Boxer AL, Staffaroni AM, Knopman DS, Sukoff Rizzo SJ, Territo PR, Arnold SE, Ballard C, Beher D, Boeve BF, Dacks PA, Diaz K, Ewen C, Fiske B, Gonzalez MI, Harris GA, Hoffman BJ, Martinez TN, McDade E, Nisenbaum LK, Palma JA, Quintana M, Rabinovici GD, Rohrer JD, Rosen HJ, Troyer MD, Kim DY, Tanzi RE, Zetterberg H, Ziogas NK, May PC, Rommel A — A framework for translating tauopathy therapeutics: Drug discovery to clinical trials Alzheimers Dement. View source
  5. Arciniega H, Baucom ZH, Tuz-Zahra F, Tripodis Y, John O, Carrington H, Kim N, Knyazhanskaya EE, Jung LB, Breedlove K, Wiegand TLT, Daneshvar DH, Rushmore RJ, Billah T, Pasternak O, Coleman MJ, Adler CH, Bernick C, Balcer LJ, Alosco ML, Koerte IK, Lin AP, Cummings JL, Reiman EM, Stern RA, Shenton ME, Bouix S — Brain morphometry in former American football players: findings from the DIAGNOSE CTE research project Brain. View source
  6. Lansdall CJ, Teng E, Chague J, Palanganda R, Delmar P, Smith J, Cummings JL, McDougall F — Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease Alzheimers Dement. View source
  7. Su C, Hou Y, Xu J, Xu Z, Zhou M, Ke A, Li H, Xu J, Brendel M, Maasch JRMA, Bai Z, Zhang H, Zhu Y, Cincotta MC, Shi X, Henchcliffe C, Leverenz JB, Cummings J, Okun MS, Bian J, Cheng F, Wang F — Identification of Parkinson's disease PACE subtypes and repurposing treatments through integrative analyses of multimodal data NPJ Digit Med. View source
  8. Duff K, Miller JB, Cobos K, Rodrigues J, O'Bryant SE; HABS-HD Team — Derivation of Indices of Cognitive Change Among Hispanic Adults and Elders JAMA Netw Open. View source
  9. Zhuang X, Moshi MA, Quinones O, Trenholm RA, Chang CL, Cordes D, Vanderford BJ, Vo V, Gerrity D, Oh EC — Drug Use Patterns in Wastewater and Socioeconomic and Demographic Indicators JAMA Netw Open. View source
  10. Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J — Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development CNS Drugs. View source
  11. Raket LL, Cummings J, Moscoso A, Villain N, Schöll M — Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease Alzheimers Dement. View source
  12. Angioni D, Cummings J, Lansdall CJ, Middleton L, Sampaio C, Gauthier S, Cohen S, Petersen RC, Rentz DM, Wessels AM, Hendrix SB, Jessen F, Carrillo MC, Doody RS, Irizarry M, Andrews JS, Vellas B, Aisen P — Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force The journal of prevention of Alzheimer's disease. View source

Publications in 2023

  1. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F — Alzheimer's disease drug development pipeline: 2023 Alzheimers Dement (N Y). View source
  2. Zhang P, Hou Y, Tu W, Campbell N, Pieper AA, Leverenz JB, Gao S, Cummings J, Cheng F — Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans Alzheimers Dement. View source
  3. Eyre HA, Lundin R, Falcão VP, Berk M, Hawrot T, Leboyer M, Destrebecq F, Sarnyai Z, Reynolds C 3rd, Lavretsky H, Kolappa K, Cummings J — Brain Health Is a Determinant of Mental Health Am J Geriatr Psychiatry. View source
  4. Cummings J — Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics Drugs. View source
  5. Alosco ML, Tripodis Y, Baucom ZH, Adler CH, Balcer LJ, Bernick C, Mariani ML, Au R, Banks SJ, Barr WB, Wethe JV, Cantu RC, Coleman MJ, Dodick DW, McClean MD, McKee AC, Mez J, Palmisano JN, Martin B, Hartlage K, Lin AP, Koerte IK, Cummings JL, Reiman EM, Stern RA, Shenton ME, Bouix S; DIAGNOSE CTE Research Project — White matter hyperintensities in former American football players Alzheimers Dement. View source
  6. Heino MTJ, Proverbio D, Marchand G, Resnicow K, Hankonen N — Attractor landscapes: a unifying conceptual model for understanding behaviour change across scales of observation Health Psychol Rev. View source
  7. Toller G, Cobigo Y, Callahan P, Appleby BS, Brushaber D, Domoto-Reilly K, Forsberg LK, Ghoshal N, Graff-Radford J, Graff-Radford NR, Grossman M, Heuer HW, Kornak J, Kremers W, Lapid MI, Leger G, Litvan I, Mackenzie IR, Pascual MB, Ramos EM, Rascovsky K, Rojas JC, Staffaroni AM, Tartaglia MC, Toga A, Weintraub S, Wszolek ZK, Boeve BF, Boxer AL, Rosen HJ, Rankin KP; ALLFTD consortium — Multisite ALLFTD study modeling progressive empathy loss from the earliest stages of behavioral variant frontotemporal dementia Alzheimers Dement. View source
  8. Caldwell JZK, Isenberg N — The aging brain: risk factors and interventions for long term brain health in women Curr Opin Obstet Gynecol. View source
  9. Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A — The amyloid-β pathway in Alzheimer's disease: a plain language summary Neurodegener Dis Manag. View source
  10. Sreenivasan K, Bayram E, Zhuang X, Longhurst J, Yang Z, Cordes D, Ritter A, Caldwell J, Cummings JL, Mari Z, Litvan I, Bluett B, Mishra VR — Topological reorganization of functional hubs in patients with Parkinson's disease with freezing of gait J Neuroimaging. View source
  11. Yang Z, Cummings JL, Kinney JW, Cordes D; Alzheimer’s Disease Neuroimaging Initiative — Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients Front Neurosci. View source
  12. Lawrence E, John SE, Bhatta T — Urbanicity and cognitive functioning in later life Alzheimers Dement (Amst). View source
  13. Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O'Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE — Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape Neuron. View source
  14. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S — Lecanemab: Appropriate Use Recommendations J Prev Alzheimers Dis. View source
  15. Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J — Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study EBioMedicine. View source
  16. Longhurst JK, Rider JV, Cummings JL, John SE, Poston B, Landers MR — Cognitive-motor dual-task interference in Alzheimer's disease, Parkinson's disease, and prodromal neurodegeneration: A scoping review Gait Posture. View source
  17. Cummings J — Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary Alzheimers Dement (N Y). View source
  18. Goodwin GJ, Moeller S, Nguyen A, Cummings JL, John SE — Network analysis of neuropsychiatric symptoms in Alzheimer's disease Alzheimers Res Ther. View source
  19. Cilia R, Piacentini SHMJ, Cummings J — The challenges of finding novel and effective drugs targeting dementia and neuropsychiatric disturbances in PD: Insights from the SYNAPSE trial Parkinsonism Relat Disord. View source
  20. Wong CG, Miller JB, Zhang F, Rissman RA, Raman R, Hall JR, Petersen M, Yaffe K, Kind AJ, O'Bryant SE; HABS-HD Study Team — Evaluation of Neighborhood-Level Disadvantage and Cognition in Mexican American and Non-Hispanic White Adults 50 Years and Older in the US JAMA Netw Open. View source
  21. Cummings J, Hahn-Pedersen JH, Eichinger CS, Freeman C, Clark A, Tarazona LRS, Lanctôt K — Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review Front Neurol. View source
  22. Cummings JL, Osse AML, Kinney JW — Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification Drugs. View source
  23. Eyre HA, Stirland LE, Jeste DV, Reynolds CF 3rd, Berk M, Ibanez A, Dawson WD, Lawlor B, Leroi I, Yaffe K, Gatchel JR, Karp JF, Newhouse P, Rosand J, Letourneau N, Bayen E, Farina F, Booi L, Devanand DP, Mintzer J, Madigan S, Jayapurwala I, Wong STC, Falcoa VP, Cummings JL, Reichman W, Lock SL, Bennett M, Ahuja R, Steffens DC, Elkind MSV, Lavretsky H — Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel Recommendations Am J Geriatr Psychiatry. View source
  24. Stern RA, Trujillo-Rodriguez D, Tripodis Y, Pulukuri SV, Alosco ML, Adler CH, Balcer LJ, Bernick C, Baucom Z, Marek KL, McClean MD, Johnson KA, McKee AC, Stein TD, Mez J, Palmisano JN, Cummings JL, Shenton ME, Reiman EM; DIAGNOSE CTE Research Project Investigators — Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project Alzheimers Res Ther. View source
  25. Cummings JL, Gonzalez MI, Pritchard MC, May PC, Toledo-Sherman LM, Harris GA — The therapeutic landscape of tauopathies: challenges and prospects Alzheimers Res Ther. View source
  26. Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J — Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants Alzheimers Res Ther. View source
  27. Cummings J, Leisgang Osse AM, Kinney J — Geroscience and Alzheimer's Disease Drug Development J Prev Alzheimers Dis. View source
  28. Yang Z, Sreenivasan K, Toledano Strom EN, Osse AML, Pasia LG, Cosme CG, Mugosa MRN, Chevalier EL, Ritter A, Miller JB, Cordes D, Cummings JL, Kinney JW — Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease Alzheimers Res Ther. View source
  29. Corbett A, Williams G, Creese B, Hampshire A, Hayman V, Palmer A, Filakovzsky A, Mills K, Cummings J, Aarsland D, Khan Z, Ballard C — Cognitive decline in older adults in the UK during and after the COVID-19 pandemic: a longitudinal analysis of PROTECT study data Lancet Healthy Longev. View source
  30. Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, Hobart M, Cummings JL, Grossberg GT — Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial JAMA Neurol. View source
  31. Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group — Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease N Engl J Med. View source
  32. Zang C, Zhang H, Xu J — High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data Nat Commun. View source
  33. Yang Z, Banks SJ, Ritter AR — Microglial Imaging in Alzheimer's Disease and Its Relationship to Brain Amyloid: A Human 18F-GE180 PET Study J Alzheimers Dis. View source

Publications in 2022

Publications in 2021

  1. Smith E, Ali D, Wilkerson B, Dawson WD, Sobowale K, Reynolds C — A Brain Capital Grand Strategy: toward economic reimagination Molecular Psychiatry. View source
  2. Salazar AM, Leisgang AM, Ortiz AA, Murtishaw AS, Kinney JW — Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer’s disease Neurobiol Aging. View source
  3. Sabbagh MN, Pope E, Cordes L, Shi J, DeCourt B — Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD Expert Opin Investig Drugs. View source
  4. Richardson S, Sinha A, Vahia I, Dawson W, Kaye J, Reynolds CF — Brain Health Living Labs Am J Geriatr Psychiatry. View source
  5. Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C — Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia Alzheimer’s Dement Transl Res Clin Interv. View source
  6. Hellton KH, Cummings J, Vik-Mo AO, Nordrehaug JE, Aarsland D, Selbaek G — The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory Multivariate Behav Res. View source
  7. Cummings J — New approaches to symptomatic treatments for Alzheimer’s disease Molecular Neurodegeneration. View source
  8. Cummings J — Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for alzheimer’s disease J Neuropsychiatry Clin Neurosci. View source
  9. Cummings J — The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases American Journal of Geriatric Psychiatry. View source
  10. Caldwell JZK, Kinney JW, Ritter A, Salazar A, Wong CG, Cordes D — Inflammatory cytokine levels implicated in Alzheimer’s disease moderate the effects of sex on verbal memory performance Brain Behav Immun. View source
  11. Armstrong MJ, Sullivan JL, Amodeo K, Lunde A, Tsuang DW, Reger MA — Suicide and Lewy body dementia: Report of a Lewy body dementia association working group International Journal of Geriatric Psychiatry. View source
  12. Abate G, Vezzoli M, Polito L, Guaita A, Albani D, Marizzoni M — A conformation variant of p53 combined with machine learning identifies alzheimer disease in preclinical and prodromal stages J Pers Med. View source

Publications in 2020

  1. Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J — A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer’s Disease J Alzheimer’s Dis. View source
  2. Stephen SJ, Shan G, Banks SJ, Bernick C, Bennett LL — The Relationship Between Fighting Style, Cognition, and Regional Brain Volume in Professional Combatants: A Preliminary Examination Using Brief Neurocognitive Measures J Head Trauma Rehabil. View source
  3. Yang Z, Zhuang X, Sreenivasan K, Mishra V, Curran T, Cordes D — A robust deep neural network for denoising task-based fMRI data: An application to working memory and episodic memory Med Image Anal. View source
  4. Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH — Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease Alzheimer’s Dement. View source
  5. Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS — The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years J Prev Alzheimer’s Dis. View source
  6. Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD — Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD) J Prev Alzheimer’s Dis. View source
  7. Tolar M, Abushakra S, Sabbagh M — The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis Alzheimer’s Dement. View source
  8. Ternes K, Iyengar V, Lavretsky H, Dawson WD, Booi L, Ibanez A — Brain health INnovation Diplomacy: A model binding diverse disciplines to manage the promise and perils of technological innovation International Psychogeriatrics. View source
  9. Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL — BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain Brain. View source
  10. Shan G, Zhang H, Jiang T — Correlation Coefficients for a Study with Repeated Measures Comput Math Methods Med. View source
  11. Shan G, Bayram E, Caldwell JZK, Miller JB, Shen JJ, Gerstenberger S — Partial Correlation Coefficient for a Study With Repeated Measurements Stat Biopharm Res. View source
  12. Sabbagh M, Sadowsky C, Tousi B, Agronin ME, Alva G, Armon C — Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer’s disease Alzheimer’s Dement. View source
  13. Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G — Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials J Prev Alzheimer’s Dis. View source
  14. Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS — TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology J Prev Alzheimer’s Dis. View source
  15. Jiang T, Cao B, Shan G — Accurate confidence intervals for risk difference in meta-analysis with rare events BMC Med Res Methodol. View source
  16. Hjetland GJ, Nordhus IH, Pallesen S, Cummings J, Tractenberg RE, Thun E — An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home Front Psychiatry. View source
  17. Hannestad J, Koborsi K, Klutzaritz V, Chao W, Ray R, Páez A — Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia Alzheimer’s Dement Transl Res Clin Interv. View source
  18. Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M — Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials Am J Geriatr Psychiatry. View source
  19. Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R — Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report J Prev Alzheimer’s Dis. View source
  20. Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB — Harnessing endophenotypes and network medicine for Alzheimer’s drug repurposing Medicinal Research Reviews. View source
  21. Digma LA, Madsen JR, Rissman RA, Jacobs DM, Brewer JB, Banks SJ — Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau Brain Commun. View source
  22. Decourt B, Wilson J, Ritter A, Dardis C, Difilippo FP, Zhuang X — MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to alzheimer’s disease Open Access J Clin Trials. View source
  23. Dawson WD, Bobrow K, Ibanez A, Booi L, Pintado-Caipa M, Yamamoto S — The necessity of diplomacy in brain health The Lancet Neurology. View source
  24. Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT — Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition American Journal of Geriatric Psychiatry. View source
  25. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K — Alzheimer’s disease drug development pipeline: 2020 Alzheimer’s Dement Transl Res Clin Interv. View source
  26. Cummings JL — Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach Dement Geriatr Cogn Disord. View source
  27. Cummings J — The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs J Prev Alzheimer’s Dis. View source
  28. Cummings J — The Neuropsychiatric Inventory: Development and Applications Journal of Geriatric Psychiatry and Neurology. View source
  29. Bernick C, Shan G, Zetterberg H, Banks S, Mishra VR, Bekris L — Longitudinal change in regional brain volumes with exposure to repetitive head impacts Neurology. View source
  30. Bennett LL, Stephen SJ, Bernick C, Shan G, Banks SJ — Sex Moderates the Relationship That Number of Professional Fights Has With Cognition and Brain Volumes Front Neurol. View source
  31. Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E — Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia PLoS One. View source
  32. Bayram E, Banks SJ, Shan G, Kaplan N, Caldwell JZK — Sex Differences in Cognitive Changes in de Novo Parkinson’s Disease J Int Neuropsychol Soc. View source
  33. Bauzon J, Lee G, Cummings J — Repurposed agents in the Alzheimer’s disease drug development pipeline Alzheimer’s Res Ther. View source
  34. Ballard C, Aarsland D, Cummings J, O’Brien J, Mills R, Molinuevo JL — Drug repositioning and repurposing for Alzheimer disease Nature Reviews Neurology. View source
  35. Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggiora GA — The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview J Prev Alzheimer’s Dis. View source
  36. Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ — The Future of Anti-Amyloid Trials J Prev Alzheimer’s Dis. View source

Publications in 2019

  1. Sreenivasan K, Mishra V, Bird C, Zhuang X, Yang Z, Cordes D — Altered functional network topology correlates with clinical measures in very early-stage, drug-naïve Parkinson’s disease Park Relat Disord. View source
  2. Zhuang X, Yang Z, Sreenivasan KR, Mishra VR, Curran T, Nandy R — Multivariate group-level analysis for task fMRI data with canonical correlation analysis Neuroimage. View source
  3. Zhao T, Mishra V, Jeon T, Ouyang M, Peng Q, Chalak L — Structural network maturation of the preterm human brain Neuroimage. View source
  4. Zhang H, Song Y, Jiang B, Chen B, Shan G — Two-Stage Bagging Pruning for Reducing the Ensemble Size and Improving the Classification Performance Math Probl Eng. View source
  5. Yang Z, Zhuang X, Sreenivasan K, Mishra V, Cordes D — Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model Front Neurosci [Internet]. View source
  6. Yang Z, Zhuang X, Bird C, Sreenivasan K, Mishra V, Banks S — Performing sparse regularization and dimension reduction simultaneously in multimodal data fusion Front Neurosci. View source
  7. Sorenson K, Sabbagh MN, Johnson M, Azuma T — Do Neuropsychological Profiles Differ between Amyloid PET Positive and Negative Amnestic MCI Subjects? J Alzheimers Dis Park View source
  8. Song M, Lieberman A, Fife T, Nielsen M, Hayden S, Sabbagh M — A prospective study on gait dominant normal pressure hydrocephalus Acta Neurol Scand. View source
  9. Shan G, Zhang H, Jiang T — Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping Seq Anal. View source
  10. Shan G, Zhang H — Two-stage optimal designs with survival endpoint when the follow-up time is restricted BMC Med Res Methodol. View source
  11. Shan G, Hutson A, Wilding GE, Ma C, Tian G-L — Efficient statistical inference for a parallel study with missing data by using an exact method J Biopharm Stat. View source
  12. Sabbagh MN, Hendrix S, Harrison JE — FDA position statement “Early Alzheimer’s disease: Developing drugs for treatment, Guidance for Industry.” Vol 5, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc. View source
  13. Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E — Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial Am Heart J. View source
  14. Ouyang M, Jeon T, Sotiras A, Peng Q, Mishra V, Halovanic C — Differential cortical microstructural maturation in the preterm human brain with diffusion kurtosis and tensor imaging Proc Natl Acad Sci U S A. View source
  15. Nance C, Ritter A, Miller JB, Lapin B, Banks SJ — The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease J Alzheimer’s Dis. View source
  16. Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Walsh RR — Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson’s disease Heliyon [Internet]. View source
  17. Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Banks SJ — Understanding white matter structural connectivity differences between cognitively impaired and nonimpaired active professional fighters Hum Brain Mapp. View source
  18. Mishra VR, Sreenivasan KR, Zhengshi Yang, Zhuang X, Cordes D, Mari Z — Unique white matter structural connectivity in early-stage drug-naive Parkinson disease Neurology. View source
  19. McCrudden MT, Marchand G, Schutz P — Mixed methods in educational psychology inquiry Contemporary Educational Psychology. View source
  20. Mazurenko O, Shen J, Shan G, Greenway J — Nevada’s Medicaid Expansion and Admissions for Ambulatory Care-Sensitive Conditions Am J Manag Care [Internet]. View source
  21. Mark DK, John Z, Marwan QW, Sabbagh N — Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms Neurol Ther [Internet]. View source
  22. Lue LF, Pai MC, Chen TF, Hu CJ, Huang LK, Lin WC — Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects Front Aging Neurosci. View source
  23. Lue Yu-Min Kuo Marwan Sabbagh L-F, Lue L, Kuo Y, Sabbagh M — Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology Neurol Ther [Internet]. View source
  24. Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN — Clinical drug development for dementia with Lewy bodies: past and present Expert Opinion on Investigational Drugs. View source
  25. Lee B, Bennett LL, Bernick C, Shan G, Banks SJ — The Relations among Depression, Cognition, and Brain Volume in Professional Boxers: A Preliminary Examination Using Brief Clinical Measures J Head Trauma Rehabil. View source
  26. Landers MR, Navalta JW, Murtishaw AS, Kinney JW, Pirio Richardson S — A High-Intensity Exercise Boot Camp for Persons with Parkinson Disease: A Phase II, Pragmatic, Randomized Clinical Trial of Feasibility, Safety, Signal of Efficacy, and Disease Mechanisms J Neurol Phys Ther. View source
  27. Landers MR, Johnson KN, Johnson S, Ormsby T, Salgo DC, Zorn JB — Pre-diagnosis physical activity habits are associated with age of diagnosis in Parkinson’s disease Clin Park Relat Disord. View source
  28. JB, Banks SJ — Relationship between cortical thickness and fluency in the memory disorders clinic population Neuropsychologia. View source
  29. Jalene S, Pharr J, Shan G, Poston B — Estimated Cardiorespiratory Fitness Is Associated With Reported Depression in College Students Front Physiol. View source
  30. Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B — Tau immunotherapies for Alzheimer’s disease Expert Opin Investig Drugs. View source
  31. Goud KY, Moonla C, Mishra RK, Yu C, Narayan R, Litvan I — Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management ACS Sensors. View source
  32. Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M — Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force J Prev Alzheimer’s Dis. View source
  33. Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N — Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer’s Disease J Alzheimer’s Dis. View source
  34. Feng L, Li H, Oishi K, Mishra V, Song L, Peng Q — Age-specific gray and white matter DTI atlas for human brain at 33, 36 and 39 postmenstrual weeks Neuroimage. View source
  35. El-Nazer R, Adler CH, Beach TG, Belden Christine M., Artz J, Shill HA — Regional neuropathology distribution and verbal fluency impairments in Parkinson’s disease Park Relat Disord. View source
  36. Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C — Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease Alzheimer’s Res Ther. View source
  37. Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL — Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease N Engl J Med. View source
  38. Durant J, Duff K, Miller JB — Regression-based formulas for predicting change in memory test scores in healthy older adults: Comparing use of raw versus standardized scores J Clin Exp Neuropsychol. View source
  39. Durant J, Berg J-L, Banks SJ, Kaylegian J, Miller JB — Comparing the Boston Naming Test With the Neuropsychological Assessment Battery–Naming Subtest in a Neurodegenerative Disease Clinic Population Assessment. View source
  40. Dugger BN, Hoffman BR, Scroggins A, Serrano GE, Adler CH, Shill HA — Tau immunoreactivity in peripheral tissues of human aging and select tauopathies Neurosci Lett. View source
  41. Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ — Tau and atrophy: Domain-specific relationships with cognition Alzheimer’s Res Ther. View source
  42. Cummings J, Ritter A, Rothenberg K — Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases Current Psychiatry Reports. View source
  43. Cummings J, Passmore P, McGuinness B, Mok V, Chen C, Engelborghs S — Souvenaid in the management of mild cognitive impairment: An expert consensus opinion Alzheimer’s Research and Therapy. View source
  44. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K — Alzheimer’s disease drug development pipeline: 2019 Alzheimer’s Dement Transl Res Clin Interv. View source
  45. Cummings J, Feldman HH, Scheltens P — The “rights” of precision drug development for Alzheimer’s disease Alzheimer’s Research and Therapy. View source
  46. Cummings J, Blennow K, Johnson K, Keeley M., Bateman RJ, Molinuevo JL — Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force J Prev Alzheimer’s Dis. View source
  47. Cummings JL, Tong G, Ballard C — Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options Journal of Alzheimer’s Disease. View source
  48. Cummings J — The National Institute on Aging—Alzheimer’s Association Framework on Alzheimer’s disease: Application to clinical trials Alzheimer’s and Dementia. View source
  49. Chiu MJ, Lue LF, Sabbagh MN, Chen TF, Chen HH, Yang SY — Long-Term Storage Effects on Stability of Aβ1-40, Aβ1-42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays Dement Geriatr Cogn Dis Extra. View source
  50. Caldwell JZK, Zhuang X, Leavitt MJ, Banks SJ, Cummings J, Cordes D — Sex moderates amyloid and apolipoprotein ε4 effects on default mode network connectivity at rest Front Neurol. View source
  51. Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O — Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume Alzheimer’s Res Ther. View source
  52. Brunet HE, Miller JB, Shi J, Chung B, Munter BT, Sabbagh MN — Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? Alzheimer’s Dement Diagnosis, Assess Dis Monit View source
  53. Brunet HE, Caldwell JZK, Brandt J, Miller JB — Influence of sex differences in interpreting learning and memory within a clinical sample of older adults Aging, Neuropsychol Cogn. View source
  54. Brunet HE — P, Cummings JL. MS, Banks SJ. P, Miller JP. Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults Aware Psychiatr Symptoms a Mix Clin Sample Older Adults. View source
  55. Bernard K, Gouttefangeas S, Bretin S, Galtier S, Robert P, Holthoff-Detto V — A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer’s disease and depressive symptoms Alzheimer’s Dement Transl Res Clin Interv. View source
  56. Bennett LL, Arias JJ, Ford PJ, Bernick C, Banks SJ — Concussion reporting and perceived knowledge of professional fighters Phys Sportsmed. View source
  57. Bayram E, Shan G, Cummings JL — Associations between comorbid TDP-43, Lewy body pathology, and neuropsychiatric symptoms in Alzheimer’s disease J Alzheimer’s Dis. View source
  58. Bayram E, Kaplan N, Shan G, Caldwell JZK — The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson’s Disease Aging, Neuropsychol Cogn. View source
  59. Bayram E, Bluett B, Zhuang X, Cordes D, LaBelle DR, Banks SJ — Neural correlates of distinct cognitive phenotypes in early Parkinson’s disease J Neurol Sci. View source
  60. Banks SJ, Shifflett B, Berg JL, Sundermann E, Peavy G, Bondi MW — Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  61. Banks SJ, Bayram E, Shan G, LaBelle DR, Bluett B — Non-motor predictors of freezing of gait in Parkinson’s disease Gait Posture. View source
  62. Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL — Enrichment factors for clinical trials in mild-to-moderate Alzheimer’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  63. Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN — Unified staging system for Lewy body disorders: Clinicopathologic correlations and comparison to Braak staging J Neuropathol Exp Neurol. View source

Publications in 2018

  1. Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R — Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 Anal Relatsh Cogn Impair Funct Impair Mild Alzheimer’s Dis Exped 3. View source
  2. Zhuang X, Walsh RR, Sreenivasan K, Yang Z, Mishra V, Cordes D — Incorporating spatial constraint in co-activation pattern analysis to explore the dynamics of resting-state networks: An application to Parkinson’s disease Neuroimage. View source
  3. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B — Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease N Engl J Med. View source
  4. Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W — A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease Neurology. View source
  5. Marchand GC, Hilpert JC, Bragg KM, Cummings J — Network-based assessment of collaborative research in neuroscience Alzheimer’s Dement Transl Res Clin Interv. View source
  6. Yang Z, Zhuang X, Sreenivasan K, Mishra V, Curran T, Byrd R — 3D spatially-adaptive canonical correlation analysis: Local and global methods Neuroimage. View source
  7. Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S — Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  8. Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K — Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer’s disease biomarkers Alzheimer’s Dement. View source
  9. Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL — Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer’s disease: Results of a randomized, double-blinded, pilot study Exp Gerontol. View source
  10. Taasoobshirazi G, Puckett C, Marchand G — Stereotype Threat and Gender Differences in Biology Int J Sci Math Educ. View source
  11. Sharma S, Young RJ, Chen J, Chen X, Oh EC, Schiller MR — Minimotifs dysfunction is pervasive in neurodegenerative disorders Alzheimer’s Dement Transl Res Clin Interv. View source
  12. Shan G, Zhang H, Jiang T — Determining sample size for a binary diagnostic test in the presence of verification bias J Biopharm Stat. View source
  13. Shan G, Kang L, Xiao M, Zhang H, Jiang T — Accurate unconditional p-values for a two-arm study with binary endpoints J Stat Comput Simul. View source
  14. Shan G, Chen JJ — Optimal inference for Simon’s two-stage design with over or under enrollment at the second stage Commun Stat - Simul Comput. View source
  15. Shan G, Bernick C, Banks S — Sample size determination for a matched-pairs study with incomplete data using exact approach Br J Math Stat Psychol. View source
  16. Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J — Statistical advances in clinical trials and clinical research Alzheimer’s Dement Transl Res Clin Interv. View source
  17. Shan G — Exact confidence limits for the probability of response in two-stage designs Statistics (Ber). View source
  18. Shan G — Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage Stat Methods Med Res. View source
  19. Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J — Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force J Prev Alzheimer’s Dis. View source
  20. Murtishaw AS, Heaney CF, Bolton MM, Belmonte KCD, Langhardt MA, Kinney JW — Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer’s disease and vascular dementia Neuropharmacology. View source
  21. Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J — Current state of Alzheimer’s fluid biomarkers Acta Neuropathol. View source
  22. Miller JB, Shan G, Lombardo J, Jimenez-Maggoria G — Biomedical informatics applications for precision management of neurodegenerative diseases Alzheimer’s Dement Transl Res Clin Interv. View source
  23. Miller JB, Cummings J, Nance C, Ritter A — Neuroscience learning from longitudinal cohort studies of Alzheimer’s disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience Alzheimer’s and Dementia: Translational Research and Clinical Interventions. View source
  24. Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA — Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease PLoS One. View source
  25. Lee BG, Leavitt MJ, Bernick CB, Leger GC, Rabinovici G, Banks SJ — A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date J Neurotrauma. View source
  26. Hilpert JC, Marchand GC — Complex Systems Research in Educational Psychology: Aligning Theory and Method Educ Psychol. View source
  27. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC — Precision pharmacology for Alzheimer’s disease Pharmacological Research. View source
  28. Finger E, Berry S, Cummings J, Coleman K, Hsiung R, Feldman HH — Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY) Alzheimer’s Res Ther. View source
  29. Cummings J, Reiber C, Kumar P — The price of progress: Funding and financing Alzheimer’s disease drug development Alzheimer’s Dement Transl Res Clin Interv. View source
  30. Cummings J, Lee G, Ritter A, Zhong K — Alzheimer’s disease drug development pipeline: 2018 Alzheimer’s Dement Transl Res Clin Interv. View source
  31. Cummings J, Fox N, Vellas B, Aisen P, Shan G, EU/US Alzheimer’s Disease Task Force — Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force J Prev Alzheimer’s Dis. View source
  32. Cummings JL, Fulkerson N — Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods Alzheimer’s and Dementia: Translational Research and Clinical Interventions. View source
  33. Cummings JL, Atri A, Ballard C, Boneva N, Frolich L, Molinuevo JL — Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program Alzheimers Res Ther. View source
  34. Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V — Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  35. Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ — Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume J Alzheimer’s Dis. View source
  36. Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J — Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  37. Bernick C, Zetterberg H, Shan G, Banks S, Blennow K — Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study J Neurotrauma. View source
  38. Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB — Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study J Alzheimer’s Dis. View source
  39. Bayram E, Caldwell JZK, Banks SJ — Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer’s disease Alzheimer’s and Dementia: Translational Research and Clinical Interventions. View source
  40. Banks SJ, Zhuang X, Bayram E, Bird C, Cordes D, Caldwell JZK — Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer’s Disease J Alzheimer’s Dis. View source
  41. Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B — Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study [Internet]. Vol 17, Articles Lancet Neurology. View source
  42. Baer M, Klemetson B, Scott D, Murtishaw AS, Navalta JW, Kinney JW — Effects of Fatigue on Balance in Individuals with Parkinson Disease: Influence of Medication and Brain-Derived Neurotrophic Factor Genotype In: Journal of Neurologic Physical Therapy. Lippincott Williams and Wilkins. View source
  43. Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N — Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials In: JAMA - Journal of the American Medical Association. American Medical Association. View source
  44. Aslam S, Fritz MA, Cordes L, Sabbagh MN — What Promises the CJD Diagnosis in a Case of Rapidly Progressive Dementia? J Alzheimer’s Dis Park View source

Publications in 2017

  1. Whittaker A, Smith KP, Shan G — Pharmacy residency school-wide match rates and modifiable predictors in ACPE-accredited colleges and schools of pharmacy Am J Pharm Educ. View source
  2. Zink DN, Miller JB, Caldwell JZK, Bird C, Banks SJ — The relationship between neuropsychological tests of visuospatial function and lobar cortical thickness J Clin Exp Neuropsychol. View source
  3. Zhuang X, Yang Z, Curran T, Byrd R, Nandy R, Cordes D — A family of locally constrained CCA models for detecting activation patterns in fMRI Neuroimage. View source
  4. Zhang H, Shan G, Young D — Comparison of unweighted and weighted rank based tests for an ordered alternative in randomized complete block designs Commun Stat - Simulations Comput. View source
  5. Zhang H, Jiang T, Shan G, Xu S, Song Y — Gaussian network model can be enhanced by combining solvent accessibility in proteins Sci Rep. View source
  6. Sreenivasan K, Zhuang X, Banks SJ, Mishra V, Zhengshi Y, Gopikrishna D — Olfactory Network Differences in Master Sommeliers: Connectivity Analysis Using Granger Causality and Graph Theoretical Approach Brain Connect. View source
  7. Shan G, Zhang H, Jiang T — Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints BMC Med Res Methodol. View source
  8. Shan G, Gerstenberger S — Fisher’s exact approach for post hoc analysis of a chi-squared test PLoS One. View source
  9. Shan G, Chen JJ, Ma C — Boundary problem in Simon’s two-stage clinical trial designs J Biopharm Stat. View source
  10. Ritter A, Hawley N, Banks SJ, Miller JB — The Association between Montreal Cognitive Assessment Memory Scores and Hippocampal Volume in a Neurodegenerative Disease Sample J Alzheimer’s Dis. View source
  11. Ritter AR, Leger GC, Miller JB, Banks SJ — Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia: How Well Do the Uniform Data Set Measures Differentiate Between Diseases? Alzheimer Dis Assoc Disord View source
  12. Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J — Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer’s disease Alzheimer’s Dement Transl Res Clin Interv. View source
  13. Mishra VR, Zhuang X, Sreenivasan KR, Banks SJ, Yang Z, Bernick C — Multimodal MR imaging signatures of cognitive impairment in active professional fighters Radiology. View source
  14. Liu X, Shan G, Tian L, Ma C-X — Exact methods for testing homogeneity of proportions for multiple groups of paired binary data Commun Stat - Simul Comput. View source
  15. Lee JK, Wu J, Banks S, Bernick C, Massand MG, Modic MT — Prevalence of traumatic findings on routine MRI in a large cohort of professional fighters Am J Neuroradiol. View source
  16. Labelle DR, Walsh RR, Banks SJ — Latent Cognitive Phenotypes in de Novo Parkinson’s Disease: A Person-Centered Approach J Int Neuropsychol Soc. View source
  17. LaBelle DR, Lee BG, Miller JB — Dissociation of Executive and Attentional Elements of the Digit Span Task in a Population of Older Adults: A Latent Class Analysis Assessment. View source
  18. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE — The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations J Alzheimer’s Dis. View source
  19. Durant J, Berg J-L, Banks SJ, Miller JB — Comparing the test of practical judgment with the neuropsychological assessment battery judgment subtest in a neurodegenerative disease clinic population Appl Neuropsychol Adult.
  20. Cummings J, Scheltens P, Mckeith I, Blesa R, Harrison JE, Bertolucci PHF — Effect size analyses of souvenaid in patients with Alzheimer’s disease J Alzheimer’s Dis. View source
  21. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K — Alzheimer’s disease drug development pipeline: 2017 Alzheimer’s and Dementia: Translational Research and Clinical Interventions. View source
  22. Cummings J — Disease modification and Neuroprotection in neurodegenerative disorders Translational Neurodegeneration. View source
  23. Cummings J, Fox N — DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE J Prev Alzheimer’s Dis. View source
  24. Cordes D, Yang Z, Zhuang X, Sreenivasan K, Mishra V, Hua LH — A new algebraic method for quantitative proton density mapping using multi-channel coil data Med Image Anal. View source
  25. Caldwell JZK, Berg JL, Cummings JL, Banks SJ — Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume Alzheimer’s Res Ther. View source
  26. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG — Understanding falls in progressive supranuclear palsy Park Relat Disord. View source
  27. Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B — Effects of Risperidone and Galantamine Treatment on Alzheimer’s Disease Biomarker Levels in Cerebrospinal Fluid J Alzheimers Dis. View source
  28. Banks SJ, Miller JB, Rissman RA, Bernick CB — Lack of Influence of Apolipoprotein E Status on Cognition or Brain Structure in Professional Fighters J Neurotrauma. View source
  29. Atri A, Frölich L, Ballard C, Tariot P, Molinuevo JL, Boneva N — IDALOPIRDINE, A 5-HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’s DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM J Alzheimer’s Assoc. View source
  30. Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L — On the path to 2025: Understanding the Alzheimer’s disease continuum Alzheimer’s Research and Therapy. View source
  31. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J — CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL Hournal Prev Alzheimer’s Dis. View source

Publications in 2016

  1. Berg J-L, Swan NM, Banks SJ, Miller JB — Atypical performance patterns on Delis–Kaplan Executive Functioning System Color–Word Interference Test: Cognitive switching and earning ability in older adults J Clin Exp Neuropsychol. View source
  2. Zhang H, Jiang T, Shan G — Identification of hot spots in protein structures using Gaussian network model and Gaussian naive bayes Biomed Res Int. View source
  3. Zenisek R, Millis SR, Banks SJ, Miller JB — Prevalence of below-criterion Reliable Digit Span scores in a clinical sample of older adults Arch Clin Neuropsychol. View source
  4. Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q — Incidence of dementia and subtypes: A cohort study in four regions in China Alzheimer’s Dement. View source
  5. Xu J, Shan G, Amei A, Zhao J, Young D, Clark S — A modified Friedman test for randomized complete block designs Commun Stat - Simul Comput. View source
  6. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L — ADCOMS: A composite clinical outcome for prodromal Alzheimer’s disease trials J Neurol Neurosurg Psychiatry. View source
  7. Sunny CE, Taasoobshirazi G, Clark L, Marchand G — Stereotype threat and gender differences in chemistry Instr Sci. View source
  8. Shen JJ, Cochran CR, Mazurenko O, Moseley CB, Shan G, Mukalian R — Racial and insurance status disparities in patient safety indicators among hospitalized patients Ethn Dis. View source
  9. Shan G, Zhang H, Jiang T, Peterson H, Young D, Ma C — Exact p-Values for Simon’s Two-Stage Designs in Clinical Trials Stat Biosci. View source
  10. Shan G, Zhang H, Jiang T — Minimax and admissible adaptive two-stage designs in phase II clinical trials BMC Med Res Methodol. View source
  11. Shan G, Wilding GE, Hutson AD, Gerstenberger S — Optimal adaptive two-stage designs for early phase II clinical trials Stat Med. View source
  12. Shan G — Sample size calculation for agreement between two raters with binary endpoints using exact tests Stat Methods Med Res. View source
  13. Shan G — Exact sample size determination for the ratio of two incidence rates under the Poisson distribution Comput Stat. View source
  14. Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J — CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE J Prev Alzheimer’s Dis. View source
  15. Kim HJ, Choi KH, Kim SH, Cummings JL, Yang DW — Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory Dement Geriatr Cogn Dis Extra. View source
  16. Jacobs J, Banks S, Zelmann R, Zijlmans M, Jones-Gotman M, Gotman J — Spontaneous ripples in the hippocampus correlate with epileptogenicity and not memory function in patients with refractory epilepsy Epilepsy Behav. View source
  17. Izuora KE, Ezeanolue EE, Neubauer MF, Gewelber CL, Allenback GL, Shan G — Changes in Inflammatory and Bone Turnover Markers After Periodontal Disease Treatment in Patients With Diabetes [Internet] View source
  18. Durant J, Leger GC, Banks SJ, Miller JB — Relationship between the Activities of Daily Living Questionnaire and the Montreal Cognitive Assessment Alzheimer’s Dement Diagnosis, Assess Dis Monit. View source
  19. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S — Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria Alzheimer’s and Dementia. View source
  20. Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G — Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer’s Disease and Dementia with Lewy Bodies CNS Neurosci Ther. View source
  21. Cummings J, Aisen PS, Dubois B, Frölich L, Jack CR, Jones RW — Drug development in Alzheimer’s disease: The path to 2025 Alzheimer’s Res Ther. View source
  22. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A — Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease Alzheimer’s Res Ther. View source
  23. Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J — RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK J Prev Alzheimer’s Dis. View source
  24. Berg J-L, Durant J, Banks SJ, Miller JB — Estimates of premorbid ability in a neurodegenerative disease clinic population: comparing the Test of Premorbid Functioning and the Wide Range Achievement Test, 4th Edition Clin Neuropsychol. View source
  25. Banks SJ, Sreenivasan KR, Weintraub DM, Baldock D, Noback M, Pierce ME — Structural and functional MRI differences in master sommeliers: A pilot study on expertise in the brain Front Hum Neurosci. View source
  26. Baldock D, Miller JB, Leger GC, Banks SJ — Memory Test Performance on Analogous Verbal and Nonverbal Memory Tests in Patients with Frontotemporal Dementia and Alzheimer’s Disease Dement Geriatr Cogn Dis Extra. View source
  27. Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL — REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE J Prev Alzheimer’s Dis. View source
  28. Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA — CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT.” J Prev Alzheimer’s Dis View source

Publications in 2015

  1. Mazurenko O, Gupte G, Shan G — Analyzing U.S nurse turnover: Are nurses leaving their jobs or the profession itself? J Hosp Adm. View source
  2. Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR — A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) J Prev Alzheimer’s Dis. View source
  3. Wang W, Shan G — Exact confidence intervals for the relative risk and the odds ratio Biometrics. View source
  4. Vogel SJ, Banks SJ, Cummings JL, Miller JB — Concordance of the Montreal cognitive assessment with standard neuropsychological measures Alzheimer’s Dement Diagnosis, Assess Dis Monit. View source
  5. Soto M, Abushakra S, Cummings J, Siffert J, Robert P, Vellas B — PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE J Prev Alzheimer’s Dis. View source
  6. Shan G, Amei A, Young D — Efficient noninferiority testing procedures for simultaneously assessing sensitivity and specificity of two diagnostic tests Comput Math Methods Med. View source
  7. Shan G — Improved confidence intervals for the Youden Index PLoS One. View source
  8. Shan G — Exact confidence intervals for randomized response strategies J Appl Stat. View source
  9. Ritter A, Cummings J — Fluid biomarkers in clinical trials of Alzheimer’s disease therapeutics Frontiers in Neurology. View source
  10. Pakhomov SVS, Marino SE, Banks S, Bernick C — Using automatic speech recognition to assess spoken responses to cognitive tests of semantic verbal fluency Speech Commun. View source
  11. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL — Alzheimer’s disease Nature Reviews Disease Primers. View source
  12. Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ — Values of the minimal clinically important difference for the neuropsychiatric inventory questionnaire in individuals with dementia J Am Geriatr Soc. View source
  13. Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS — Alzheimer’s disease progression by geographical region in a clinical trial setting Alzheimer’s Res Ther. View source
  14. Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF — Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials Alzheimer’s Res Ther. View source
  15. Ghazi-Saidi L, Walsh RR, Shan G, Banks SJ — Biomarkers of Cognitive Impairment Brain Cortical Thickness, Volumetrics, and Cerebrospinal Fluid [Internet] Alzheimer Dis Assoc Disord. Available from:. View source
  16. Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW — Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial JAMA - J Am Med Assoc. View source
  17. Cummings J, Zhong K — Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer’s Disease Clin Pharmacol Ther. View source
  18. Bonner-Jackson A, Mahmoud S, Miller J, Banks SJ — Verbal and non-verbal memory and hippocampal volumes in a memory clinic population Alzheimer’s Res Ther. View source